We advised WSE-listed Bioceltix S.A. on a non-brokered public offering of the Company’s shares

We advised WSE-listed Bioceltix S.A. on a non-brokered public offering of the Company’s shares carried out under the accelerated book-building (ABB) procedure and a related private placement of the Company’s new issue shares.

The public offering included 400,000 new issue series K shares and 150,000 existing shares of the Company, admitted to trading on the regulated market of the WSE, offered by its shareholder, Kvarko Group ASI sp. z o.o.

The public offering was targeted at qualified investors and selected retail investors. As part of the private placement, the Company issued 150,000 series L shares, which were subscribed for by Kvarko Group ASI sp. z o.o. in order to reinvest the funds raised from the sale of the Company’s shares in the public offering.

The total value of the public offering and the private placement amounted to PLN 25,900,000.

We supported the Company in all legal aspects of the transaction. The scope of consulting included, in particular, advising on the transaction structuring process, preparation and negotiation of transaction documentation (including the investment agreement, issue documentation), advising on the implementation of the Company’s disclosure obligations, and providing legal advice on the process of dematerialization of new issue shares and admission of series K shares to trading on the regulated market of the WSE.

Bookkeeping for the shares offered in the public offering was entrusted to Navigator Brokerage House S.A. In terms of Investor Relations, the Company was also supported by cc group.
We thank Bioceltix S.A. and the other advisors involved in the transaction for their valuable cooperation and trust.